X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES JUBILANT LIFE SCIENCES VENUS REMEDIES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -693.1 26.3 - View Chart
P/BV x 0.2 5.4 3.8% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 VENUS REMEDIES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
VENUS REMEDIES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs218187 116.7%   
Low Rs8265 126.1%   
Sales per share (Unadj.) Rs365.6364.3 100.3%  
Earnings per share (Unadj.) Rs1.56.8 21.7%  
Cash flow per share (Unadj.) Rs37.924.5 154.8%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %02.4 0.0%  
Book value per share (Unadj.) Rs382.5164.9 232.0%  
Shares outstanding (eoy) m11.44159.28 7.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.3 118.7%   
Avg P/E ratio x101.018.4 548.8%  
P/CF ratio (eoy) x4.05.1 77.0%  
Price / Book Value ratio x0.40.8 51.4%  
Dividend payout %043.8 0.0%   
Avg Mkt Cap Rs m1,71720,061 8.6%   
No. of employees `0001.06.2 16.5%   
Total wages/salary Rs m32411,052 2.9%   
Avg. sales/employee Rs Th4,100.79,383.0 43.7%   
Avg. wages/employee Rs Th318.01,786.9 17.8%   
Avg. net profit/employee Rs Th16.7176.3 9.5%   
INCOME DATA
Net Sales Rs m4,18358,034 7.2%  
Other income Rs m20191 10.5%   
Total revenues Rs m4,20358,224 7.2%   
Gross profit Rs m8125,786 14.0%  
Depreciation Rs m4172,812 14.8%   
Interest Rs m3803,237 11.7%   
Profit before tax Rs m35-72 -48.7%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m18696 2.6%   
Profit after tax Rs m171,090 1.6%  
Gross profit margin %19.410.0 194.6%  
Effective tax rate %51.6-965.9 -5.3%   
Net profit margin %0.41.9 21.6%  
BALANCE SHEET DATA
Current assets Rs m2,77129,280 9.5%   
Current liabilities Rs m1,93138,912 5.0%   
Net working cap to sales %20.1-16.6 -120.9%  
Current ratio x1.40.8 190.6%  
Inventory Days Days12584 148.2%  
Debtors Days Days5451 106.0%  
Net fixed assets Rs m5,32855,712 9.6%   
Share capital Rs m114155 74.0%   
"Free" reserves Rs m4,17720,968 19.9%   
Net worth Rs m4,37626,265 16.7%   
Long term debt Rs m1,91117,169 11.1%   
Total assets Rs m8,42888,606 9.5%  
Interest coverage x1.11.0 111.7%   
Debt to equity ratio x0.40.7 66.8%  
Sales to assets ratio x0.50.7 75.8%   
Return on assets %4.74.9 96.4%  
Return on equity %0.44.2 9.4%  
Return on capital %6.611.6 57.1%  
Exports to sales %037.8 0.0%   
Imports to sales %20.516.5 124.5%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs m8589,567 9.0%   
Fx inflow Rs m022,004 0.0%   
Fx outflow Rs m85811,749 7.3%   
Net fx Rs m-85810,255 -8.4%   
CASH FLOW
From Operations Rs m4698,026 5.8%  
From Investments Rs m29-1,744 -1.7%  
From Financial Activity Rs m-464-4,447 10.4%  
Net Cashflow Rs m351,834 1.9%  

Share Holding

Indian Promoters % 32.9 45.6 72.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 0.2 8.7 2.1%  
FIIs % 0.6 21.2 2.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 21.1 314.7%  
Shareholders   20,121 23,815 84.5%  
Pledged promoter(s) holding % 36.4 15.9 229.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - FDC LTD. COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS